These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38614152)

  • 1. Fluorine-18 labeling PEGylated 6-boronotryptophan for PET scanning of mice for assessing the pharmacokinetics for boron neutron capture therapy of brain tumors.
    Chen XP; Hsu FC; Huang KY; Hsieh TS; Farn SS; Sheu RJ; Yu CS
    Bioorg Med Chem Lett; 2024 Jun; 105():129744. PubMed ID: 38614152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
    Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
    J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
    Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
    J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive estimation of
    Yoshimoto M; Honda N; Kurihara H; Hiroi K; Nakamura S; Ito M; Shikano N; Itami J; Fujii H
    Cancer Sci; 2018 May; 109(5):1617-1626. PubMed ID: 29498142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
    Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography.
    Nichols TL; Kabalka GW; Miller LF; Khan MK; Smith GT
    Med Phys; 2002 Oct; 29(10):2351-8. PubMed ID: 12408309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model.
    Iguchi Y; Michiue H; Kitamatsu M; Hayashi Y; Takenaka F; Nishiki T; Matsui H
    Biomaterials; 2015 Jul; 56():10-7. PubMed ID: 25934274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the total distribution volume of
    Romanov V; Isohashi K; Alobthani G; Beshr R; Horitsugi G; Kanai Y; Naka S; Watabe T; Shimosegawa E; Hatazawa J
    Ann Nucl Med; 2020 Mar; 34(3):155-162. PubMed ID: 31808134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Borono-2-
    Ishiwata K
    Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.
    Li J; Shi Y; Zhang Z; Liu H; Lang L; Liu T; Chen X; Liu Z
    Bioconjug Chem; 2019 Nov; 30(11):2870-2878. PubMed ID: 31593447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar T/N ratio between
    Lin YC; Chou FI; Yang BH; Chang CW; Chen YW; Hwang JJ
    Ann Nucl Med; 2020 Jan; 34(1):58-64. PubMed ID: 31650410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of Boron Compound Concentration for BNCT Using Positron Emission Tomography.
    Balcerzyk M; De-Miguel M; Guerrero C; Fernandez B
    Cells; 2020 Sep; 9(9):. PubMed ID: 32932575
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
    Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and subcellular localization of an unnatural boron-containing amino acid (cis-ABCPC) by imaging secondary ion mass spectrometry for neutron capture therapy of melanomas and gliomas.
    Chandra S; Barth RF; Haider SA; Yang W; Huo T; Shaikh AL; Kabalka GW
    PLoS One; 2013; 8(9):e75377. PubMed ID: 24058680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
    Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
    J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT).
    Lee W; Sarkar S; Ahn H; Kim JY; Lee YJ; Chang Y; Yoo J
    Biochem Biophys Res Commun; 2020 Feb; 522(3):669-675. PubMed ID: 31787237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT).
    Wu CY; Lin JJ; Chang WY; Hsieh CY; Wu CC; Chen HS; Hsu HJ; Yang AS; Hsu MH; Kuo WY
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110387. PubMed ID: 31394419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
    Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
    BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
    Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma.
    Chen JC; Chang SM; Hsu FY; Wang HE; Liu RS
    Appl Radiat Isot; 2004 Nov; 61(5):887-91. PubMed ID: 15308163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.